Assignee
GASHERBRUM BIO INC
US·9 granted patents·18 pending applications·21 citations·filing 2021–2025
Top patents by PatentIndex Score
27 records- 0194US11926626B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2022·Granted Mar 12, 2024·7 cites·23 claims
- 0294US11492365B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2022·Granted Nov 8, 2022·6 cites·15 claims
- 0393US12221442B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2024·Granted Feb 11, 2025·3 cites·4 claims
- 0492US12291529B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2024·Granted May 6, 2025·2 cites·28 claims
- 0592US11897851B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2023·Granted Feb 13, 2024·3 cites·5 claims
- 0682US2025115606A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2024·Application pending·0 cites
- 0781US2026055069A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2025·Application pending·0 cites
- 0876US12528781B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2023·Granted Jan 20, 2026·0 cites·21 claims
- 0975US2023071840A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2022·Application pending·0 cites
- 1074US2024327404A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2024·Application pending·0 cites
- 1171US11926643B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2022·Granted Mar 12, 2024·0 cites·20 claims
- 1265US2025019389A1Heterocyclic agonistsGASHERBRUM BIO INC·Filed 2024·Application pending·0 cites
- 1362US12552791B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2025·Granted Feb 17, 2026·0 cites·27 claims
- 1461US2023295154A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 1560US2025250269A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1660US2025206757A15,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetesGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1760US2025109148A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1858US2025145596A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1958US2025177362A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 2058US2024366639A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2022·Application pending·0 cites
- 2155US12595264B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2021·Granted Apr 7, 2026·0 cites·24 claims
- 2255US2023391760A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 2353US2024083886A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 2453US2024360166A1Salts and solid forms of a compound having glp-1 agonist activityGASHERBRUM BIO INC·Filed 2024·Application pending·0 cites
- 2553US2023322771A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 2650US2023165846A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 2749US2025188103A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when GASHERBRUM BIO INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →